Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A study to evaluate the Use of Rosuvastatin in subjects On Regular haemodialysis: an Assessment of survival and cardiovascular events (AURORA). A double-blind , randomised, phase 3b, parallel-group study to compare the effects of rosuvastatin with placebo on assessment of survival and cardiovascular events when given to subjects with end-stage renal failure on chronic haemodialysis treatment

Next Previous
X
Search
Trial Profile

A study to evaluate the Use of Rosuvastatin in subjects On Regular haemodialysis: an Assessment of survival and cardiovascular events (AURORA). A double-blind , randomised, phase 3b, parallel-group study to compare the effects of rosuvastatin with placebo on assessment of survival and cardiovascular events when given to subjects with end-stage renal failure on chronic haemodialysis treatment

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 14 Jun 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rosuvastatin (Primary)
  • Indications Cardiovascular disorders; Myocardial infarction; Stroke
  • Focus Registrational; Therapeutic Use
  • Acronyms AURORA
  • Sponsors AstraZeneca

    • Most Recent Events

    • 01 Jun 2022 Results of an analysis assessed the Serum markers of fibrosis, cardiovascular and all-cause mortality in hemodialysis patients published in the Clinical Research in Cardiology
    • 01 Apr 2022 Results of post hoc analysis assessing efficacy according to serum phosphate levels published in the Clinical Journal of The American Society of Nephrology: CJASN
    • 10 Nov 2009 Actual number of patients changed from 2775 to 2776 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top